Pfizer's Daurismo (glasdegib) Receives FDA Approval for Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML)
Shots:
- The approval is based on P-II BRIGHT (1003) trial study results assessing Daurismo + cytarabine (LDAC) & daunorubicin vs PBO + cytarabine & daunorubicin in 115 patients in ratio (2:1) with newly diagnosed AML
- The P-II BRIGHT (1003) study resulted in median OS 8.3 mos and 54% reduction in the risk of death for patients
- Daurismo (glasdegib) is an oral qd Hedgehog pathway inhibitor indicated for the treatment of patients with newly diagnosed AML in adult patients who are >75 years
Click here Ref: Pfizer | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com